alpha-Hemolysin Variants with Altered Characteristics
US-2017088588-A1 · Mar 30, 2017 · US
US10227645B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10227645-B2 |
| Application number | US-201615274770-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 23, 2016 |
| Priority date | Sep 24, 2015 |
| Publication date | Mar 12, 2019 |
| Grant date | Mar 12, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein are engineered alpha-hemolysin subunits having mutated oligomerization domains for assembling into heptameric nanopores in lipid bilayers.
Opening claim text (preview).
What is claimed is: 1. A hetero-oligomeric α-hemolysin (αHL) heptamer, comprising at least one preceding and at least one following subunit, each subunit comprising at least one αHL monomer and/or at least one polypeptide comprising concatenated αHL monomers, wherein the αHL monomers comprise a self-rescue mutation to enable oligomerization of said at least one preceding and one following subunit, wherein said self-rescue mutation corresponds to H35G of SEQ ID NO:3, and wherein the heptamer comprises exactly 7 αHL monomers, wherein each αHL monomer comprises a first oligomerization domain and a second oligomerization domain, wherein the first oligomerization domain of each αHL monomer is linked to the second oligomerization domain of a preceding αHL monomer and the second oligomerization domain of each αHL monomer is linked to the first oligomerization domain of a following αHL monomer. 2. The hetero-oligomeric αHL heptamer of claim 1 , wherein at least one αHL monomer further comprises a time-to-thread (TTT) substitution at a position corresponding to one or both of position 12 and position 17 of SEQ ID NO: 3. 3. An isolated polypeptide comprising one or more alpha-hemolysin monomers, the alpha-hemolysin monomers comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 3 and an H35G substitution. 4. The isolated polypeptide of claim 3 , wherein the alpha-hemolysin monomers further comprise one or more a time-to-thread (TTT) substitution at a position corresponding to position 12 and/or position 17 of SEQ ID NO: 3. 5. The isolated polypeptide of claim 4 , wherein the one or more TTT substitution is selected from the group consisting of T12K, T12R, N17K, and N17R. 6. The isolated polypeptide of claim 3 having 1 alpha-hemolysin monomer. 7. The isolated polypeptide of claim 3 having at least 2 alpha-hemolysin monomers, wherein each monomer of the polypeptide is separated from each adjacent monomer in the polypeptide by a flexible linker. 8. The isolated polypeptide of claim 7 having from 2 to 7 alpha-hemolysin monomers. 9. A heptameric pore complex comprising 7 alpha-hemolysin monomers, wherein the alpha-hemolysin monomers comprise an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 3 and an H35G substitution. 10. The heptameric pore complex of claim 9 , further comprising a polymerase linked to one of the alpha-hemolysin monomers. 11. The heptameric pore complex of claim 10 , wherein the polymerase is covalently linked to the alpha-hemolysin monomer. 12. The heptameric pore complex of claim 9 , wherein one or more of the alpha-hemolysin monomers further comprises a time-to-thread (TTT) substitution at a position corresponding to one or both of position 12 and position 17 of SEQ ID NO: 3. 13. The heptameric pore complex of claim 12 , wherein the TTT substitution or substitutions is/are selected from the group consisting of T12K, T12R, N17K, and N17R. 14. The heptameric pore complex of claim 9 , wherein each alpha-hemolysin monomer of the heptameric pore complex is disposed within a separate polypeptide from the other alpha-hemolysin monomers of the heptameric pore complex. 15. The heptameric pore complex of claim 9 , wherein from 2 to 7 of the alpha-hemolysin monomers of the heptameric pore complex are disposed on a single polypeptide. 16. A method of making a heptameric pore complex, the method comprising heating a plurality of polypeptides of claim 3 in the presence of a lipid at a temperature greater than 25° C. for a sufficient period of time for the polypeptides to self-aggregate into alpha-hemolysin heptamers. 17. The method of claim 16 , wherein the temperature at which the polypeptides are heated is 30° C. or higher. 18. The method of claim 17 , wherein the temperature at which the polypeptides are heated is from 30° C. to 50° C. 19. A chip for nucleic acid sequencing, said chip comprising a heptameric pore complex of claim 9 disposed in a membrane adjacent to or in proximity to an electrode.
being a sensor, e.g. electrode · CPC title
from Staphylococcus (G) · CPC title
Methods for sequencing · CPC title
being a biochannel or pore · CPC title
Nucleotidyltransferases (2.7.7) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.